medigraphic.com

2019, Number 5

Next >>

Rev Clin Esc Med 2019; 9 (5)

Cinacalcet en el Trastorno Mineral Óseo en el Paciente con Enfermedad Renal Crónica en Diálisis y Prediálisis

Arley VDA, Castro AE

Language: Spanish
References: 32
Page: 1-7
PDF size: 403.77 Kb.


ABSTRACT

Chronic kidney disease is a prevalent and high mortality entity, which is underdiagnosed due to global registration problems, among its complications is the bone mineral disorder which favors vascular calcifications and cardiovascular risk in this population. The use of mimetic calcium generates adequate control of secondary hyperparathyroidism in nephropathic patients on dialysis, especially when joint management is carried out with other drugs for the control of bone mineral disorder; and, it achieves a reduction in cardiovascular risk.


REFERENCES

  1. Eknoyan, G. et al. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements (2013). VOL 3 | ISSUE 1 | JANUARY (1) 2013.

  2. Webster, A. et al. Chronic kidney disease. Lancet 2017; 389: 1238–52. http://dx.doi.org/10.1016/ S0140-6736(16)32064-5

  3. Romagnani, P. Et Al. Chronic Kidney Disease. Nature Reviews | Disease Primers Volume 3 | Article Number 17088 | 3. Doi:10.1038/Nrdp.2017.88

  4. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. (2016) Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. PLoS ONE 11(7): e0158765. doi:10.1371/journal.pone.0158765

  5. Ministerio de Salud, Mortalidad Por Insuficiencia Renal Crónica: Costa Rica. (2016). Informe Estadístico.

  6. Rivera, A. et Méndez, E. Mortalidad y egresos hospitalarios por enfermedad renal crónica compatibles con enfermedad crónica de causas no tradicionales, Costa Rica. Acta méd costarric Vol 58 (1), enero-marzo 2016.

  7. Torregrosa, J. et al. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica (S.E.N.- MM). Nefrologia 2011;31(Suppl.1):3-32. doi:10.3265/ Nefrologia.pre2011.Jan.10816

  8. Eknoyan, G. et al. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease– Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements (2017) 7, 1–59. http://dx. doi.org/10.1016/j.kisu.2017.04.001.

  9. García, P. Et al. Vascular Calcification in Patients with Chronic Kidney Disease: Types, Clinical Impact and Pathogenesis. Med Princ Pract 2011;20:203–212 DOI: 10.1159/000323434.

  10. Rodríguez, M. et al. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review. Seminars in Dialysis— 2015. DOI: 10.1111/sdi.12357

  11. Querido, S. et al. Cinacalcet in peritoneal dialysis patients: one-center experience. J Bras Nefrol 2017;39(1):42-45. DOI: 10.5935/0101-2800.20170007

  12. Wheeler, D. et al. Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. Am Heart Assoc. 2014;3:e001363 doi: 10.1161/JAHA.114.001363.

  13. Parfrey, P. et al. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clin J Am Soc Nephrol 10: ccc–ccc, 2015. doi: 10.2215/CJN.07730814.

  14. Moe, S. et al. Cinacalcet, Fibroblast Growth Factor- 23, and Cardiovascular Disease in Hemodialysis. The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015;132:27-39. DOI: 10.1161/CIRCULATIONAHA. 114.013876.

  15. Floege, J. et al. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Clin J Am Soc Nephrol 10: 800–807, 2015. doi:10.2215/CJN.10221014.

  16. Friedl C, et al, Mortality in dialysis patients with cinacalcet use: A large observational registry study, Eur J Intern Med (2017), http://dx.doi.org/10.1016/j. ejim.2017.05.002

  17. Moe, S. Et al. Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. J Am Soc Nephrol 26: ccc–ccc, 2014. doi: 10.1681/ASN.2014040414

  18. Zawierucha, J. Et al. Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients. POLISH ARCHIVES OF INTERNAL MEDICINE 2017; 127 (12). doi:10.20 452/pamw.4124

  19. Bover, J. Et al. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. Clin J Am Soc Nephrol: ccc–ccc, 2015. doi: 10.2215/CJN.01760215.

  20. Brunelli, S. Et al. Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation. pharmacoepidemiology and drug safety 2015; 24: 1058–1067. DOI: 10.1002/pds.3845

  21. Cozzolino, M. Et al. Treatments for secondary hyperparathyroidism in hemodialysis. Pol Arch Intern Med. 2017; 127 (12): 807-809 doi:10.20452/ pamw.4170

  22. Akizawa, T. Et al. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Scientific RepoRts | 6:19612 | DOI: 10.1038/srep19612

  23. Jeong, S. Et al. Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients. Drug Design, Development and Therapy 2016:10 2211–2225. http://dx.doi.org/10.2147/ DDDT.S103370

  24. Moe, S. Et al. Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis. Clin J Am Soc Nephrol 12: ccc–ccc, 2017. doi: https://doi.org/10.2215/CJN.11141016

  25. Rroji, M. Et al. Calcimimetics versus parathyroidectomy: What is preferable?. International Urology and Nephrology https://doi.org/10.1007/s11255- 018-1838-5.

  26. Van der Plas, W. Et al. Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review. Nephrol Dial Transplant (2017) 32: 1902–1908 doi: 10.1093/ndt/gfx044.

  27. Lin Chen, Kongbo Wang, Shanlan Yu, Liping Lai, Xiaoping Zhang, Jingjing Yuan & Weifeng Duan (2016): Long–term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta- analysis, Renal Failure, DOI: 10.1080/0886022X.2016.1184924

  28. Sekercioglu, N. Et al. Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis. Sekercioglu et al. Systematic Reviews (2016) 5:2 DOI 10.1186/ s13643-015-0177-1

  29. Pérez-Ricart A, Galicia-Basart M, Alcalde- Rodrigo M, Segarra-Medrano A, Suñé-Negre J-M, Montoro- Ronsano J-B (2016) Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis. PLoS ONE 11(9): e0161527. doi:10.1371/ journal. pone.0161527

  30. Yuan, F. Et al. Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Blood Purif 2018;45:73–78. DOI: 10.1159/000484435.

  31. Wetmore, J. Et al. A Randomized Trial of Cinacalcet versus Vitamin D. Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 10: ccc–ccc, 2015. doi: 10.2215/CJN.07050714

  32. Nigar Sekercioglu, Jason W. Busse, M. Fatih Sekercioglu, Arnav Agarwal, Shaun Shaikh, Luciane Cruz Lopes, Reem A. Mustafa, Gordon H. Guyatt & Lehana Thabane (2016): Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis, Renal Failure, DOI: 10.3109/0886022X.2016.1172468




2020     |     www.medigraphic.com